High-dose fluconazole therapy for cancer patients with solid tumors and candidemia: An observational, noncomparative retrospective study

Supportive Care in Cancer

Volumn 12, Issue 7, 2004, Pages 511-516

  Torres, H A ^a   Kontoyiannis, D P ^a   Rolston, K V I ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cancer; Candidemia; Fluconazole

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CANCER PATIENT; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDEMIA; CANDIDIASIS; CENTRAL VENOUS CATHETER; CLINICAL ARTICLE; COLONY FORMING UNIT; DEVICE REMOVAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; FUNGEMIA; FUNGUS CULTURE; FUNGUS ISOLATION; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; NEUTROPENIA; NONHUMAN; OBSERVATION; OUTCOMES RESEARCH; PATIENT SELECTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; SOLID TUMOR; TREATMENT FAILURE;

EID: 3142735785     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-004-0601-x     Document Type: Article

References (20)

1. Anaissie EJ, Rex JH, Uzun O, Vartivarian S (1998) Predictors of adverse outcome in cancer patients with candidemia. Am J Med 104:238-245
2. Anaissie EJ, Vartivarian SE, Abi-Said D, Uzun O, Pinczowski H, Kontoyiannis DP, Khoury P, Papadakis K, Gardner A, Raad II, Gilbreath J, Bodey GP (1996) Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. Am J Med 101:170-176
3. Antoniadou A, Torres HA, Lewis RE, Thornby J, Bodey GP, Tarrand J, Han XY, Rolston KVI, Safdar A, Raad II, Kontoyiannis DP (2003) Candidemia in a Tertiary Care Cancer Center: In vitro susceptibility and its correlation with outcome of initial antifungal therapy. Medicine (Baltimore) 82:309-321
4. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, Denning DW, Donnelly JP, Edwards JE, Erjavec Z, Fiere D, Lortholary O, Maertens J, Meis JF, Patterson TF, Ritter J, Selleslag D, Shah PM, Stevens DA, Walsh TJ; Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer; Mycoses Study Group of the National Institute of Allergy and Infectious Diseases (2002) Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 34:7-14
5. Bodey GP, Mardani M, Hanna HA, Boktour M, Abbas J, Girgawy E, Hachem RY, Kontoyiannis DP, Raad II (2002) The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am J Med 112:380-385
6. Denning DW (2003) Echinocandin antifungal drugs. Lancet 362:1142-1151
7. Duswald KH, Penk A, Pittrow L (1997) High-dose therapy with fluconazole ≥800 mg day-1. Mycoses 40:267-277
8. Fraser VJ, Jones M, Dunkel J, Storfer S, Medoff G, Dunagan WC (1992) Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 15:414-421
9. Kontoyiannis DP, Lewis RE (2002) Antifungal drug resistance of pathogenic fungi. Lancet 359(9312):1135-1344
10. Mermel LA, Farr BM, Sherertz RJ, Raad II, O'Grady N, Harris JS, Craven DE; Infectious Diseases Society of America; American College of Critical Care Medicine; Society for Healthcare Epidemiology of America (2001) Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis 32:1249-1272
11. Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, Lupinacci R, Sable C, Kartsonis N, Perfect J; Caspofungin Invasive Candidiasis Study Group (2002) Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347:2020-2029
12. National Committee for Clinical Laboratory Standards (NCCLS) (1997) Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard. NCCLS document M27-A, NCCLS, Wayne
13. Nguyen MH, Peacock JE Jr, Tanner DC, Morris AJ, Nguyen ML, Snydman DR, Wagener MM, Yu VL (1995) Therapeutic approaches in patients with candidemia: evaluation in a multicenter, prospective, observational study. Arch Intem Med 155:2429-2435
14. Phillips P, Shafran S, Garber G, Rotstein C, Smaill F, Fong I, Salit I, Miller M, Williams K, Conly JM, Singer J, Ioannou S (1997) Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Eur J Clin Microbiol Infect Dis 16:337-345
15. Rex JH, Bennett JE, Sugar AM, Pappas PG, van der Horst CM, Edwards JE, Washburn RG, Scheld WM, Karchmer AW, Dine AP, Levenstein MJ, Webb CD (1994) A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 331:1325-1330
16. Rex JH, Walsh TJ, Sobel JD, Filler SG, Pappas PG, Dismukes WE, Edwards JE (2000) Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis 30:662-678
17. Rex JH, Pappas PG, Karchmer AW, Sobel J, Edwards JE, Hadley S, Brass C, Vazquez JA, Chapman SW, Horowitz HW, Zervos M, McKinsey D, Lee J, Babinchak T, Bradsher RW, Cleary JD, Cohen DM, Danziger L, Goldman M, Goodman J, Hilton E, Hyslop NE, Kett DH, Lutz J, Rubin RH, Scheld WM, Schuster M, Simmons B, Stein DK, Washburn RG, Mautner L, Chu TC, Panzer H, Rosenstein RB, Booth J; National Institute of Allergy and Infectious Diseases Mycoses Study Group (2003) A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 36:1221-1228
18. Telenti A, Steckelberg JM, Stockman L, Edson RS, Roberts GD (1991) Quantitative blood cultures in candidemia. Mayo Clin Proc 66:1120-1123
19. Warren NG, Hazen KC (1999). Candida, Cryptococcus, and other yeasts of medical importance. In: Murray PR, Baron EJ, Tenover FC, Yolken RH (eds) Manual of clinical microbiology, 7th edn. American Society for Microbiology, Washington, pp 1184-1199
20. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP (1988) Hospital acquired candidemia: the attributable mortality and excess length of stay. Arch Intern Med 148:2642-2645